Stéphane Jaisson1, Isabelle Kazes2, Aurore Desmons3, Fouad Fadel2, Jean-Baptiste Oudart3, Izabella C R Dos Santos-Weiss4, Hervé Millart5, Fatouma Touré6, Philippe Rieu6, Philippe Gillery3. 1. University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France; University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France. Electronic address: sjaisson@chu-reims.fr. 2. University Hospital of Reims, Nephrology Department, Reims, France. 3. University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France; University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France. 4. University Hospital of Reims, Maison Blanche Hospital, Laboratory of Paediatric Biology and Research, Reims, France. 5. University Hospital of Reims, Department of Pharmacology, Reims, France. 6. University of Reims Champagne-Ardenne, "Extracellular Matrix and Cell Dynamics" (MEDyC) Research Unit UMR CNRS No 7369, Reims, France; University Hospital of Reims, Nephrology Department, Reims, France.
Abstract
BACKGROUND: Homocitrulline (HCit) is a carbamylation-derived product (CDP) that has been identified as a valuable biomarker of morbidity and mortality in patients with chronic kidney disease (CKD). The aim of this study was to determine whether initiation of hemodialysis therapy (HD) could induce variations of HCit concentrations in CKD patients. METHODS: Serum HCit concentrations were determined by LC-MS/MS in CKD patients (n=108) just before (M0) and six months (M6) after the initiation of HD therapy. RESULTS: Mean HCit concentrations reached 1000μmol/mol Lysine before initiation of HD therapy and decreased by 50% within 6months after HD onset. HCit concentrations remained stable over time as assessed during a 24-months follow-up period. HCit was mostly found in its protein-bound form in HD patients. HCit concentrations obtained at M0 were positively correlated with urea (r=0.58) and carbamylated hemoglobin (r=0.41), and are likely to be promising predictive markers of mortality. However, no correlations were found between HCit concentrations and Kt/V values, suggesting that HCit is not a marker of HD efficiency. CONCLUSION: HCit concentrations reflect the intensity of protein carbamylation and are stable over time during HD treatment, making HCit a reliable biomarker in the follow-up of CKD patients.
BACKGROUND:Homocitrulline (HCit) is a carbamylation-derived product (CDP) that has been identified as a valuable biomarker of morbidity and mortality in patients with chronic kidney disease (CKD). The aim of this study was to determine whether initiation of hemodialysis therapy (HD) could induce variations of HCit concentrations in CKDpatients. METHODS: Serum HCit concentrations were determined by LC-MS/MS in CKDpatients (n=108) just before (M0) and six months (M6) after the initiation of HD therapy. RESULTS: Mean HCit concentrations reached 1000μmol/mol Lysine before initiation of HD therapy and decreased by 50% within 6months after HD onset. HCit concentrations remained stable over time as assessed during a 24-months follow-up period. HCit was mostly found in its protein-bound form in HDpatients. HCit concentrations obtained at M0 were positively correlated with urea (r=0.58) and carbamylated hemoglobin (r=0.41), and are likely to be promising predictive markers of mortality. However, no correlations were found between HCit concentrations and Kt/V values, suggesting that HCit is not a marker of HD efficiency. CONCLUSION:HCit concentrations reflect the intensity of protein carbamylation and are stable over time during HD treatment, making HCit a reliable biomarker in the follow-up of CKDpatients.
Authors: Jia Teng Sun; Ke Yang; Jing Yan Mao; Wei Feng Shen; Lin Lu; Qi Hong Wu; Yan Ping Wang; Li Ping Wu; Rui Yan Zhang Journal: J Am Heart Assoc Date: 2016-12-16 Impact factor: 5.501
Authors: Sander De Bruyne; Jonas Himpe; Sigurd E Delanghe; Griet Glorieux; Wim Van Biesen; Marc L De Buyzere; Marijn M Speeckaert; Joris R Delanghe Journal: Toxins (Basel) Date: 2020-01-26 Impact factor: 4.546